empagliflozin – Medxy AI

Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced

By MedXY 12/26/2025

This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electrolyte-stabilizing benefit of SGLT2 inhibitors.

Cardiology Clinical Updates Diabetes & Endocrinology Nephrology news

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction

By MedXY 11/28/2025

This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF patients.

Cardiology Clinical Updates Nephrology news

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

By MedXY 11/28/2025

This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin's efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.

Diabetes & Endocrinology Nephrology news

Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker

By MedXY 11/28/2025

An individual participant-level meta-analysis of 23,340 participants shows empagliflozin reduces acute and chronic kidney events, slows eGFR decline, and lowers kidney failure risk regardless of predicted acute eGFR dip, diabetes, heart failure, baseline eGFR, or albuminuria.

Diabetes & Endocrinology news

Empagliflozin, Pioglitazone or Glimepiride as Third Agents with Metformin + DPP‑4 Inhibitor: Similar HbA1c Drops but Different Trade‑offs

By MedXY 11/17/2025

A 24‑week randomized phase 4 trial found comparable HbA1c reductions when adding empagliflozin, pioglitazone or glimepiride to metformin plus a DPP‑4 inhibitor; metabolic and safety profiles differed, arguing for individualized third‑line selection.

Cardiology news Specialties

Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial

By MedXY 08/13/2025

In patients with heart failure and reduced ejection fraction, anaemia predicts iron homeostasis disruption and influences response to empagliflozin, which increases myocardial iron and improves cardiac function and exercise capacity.

Cardiology Clinical Updates news Specialties

Empagliflozin’s Impact on Peripheral Microvascular Function in HFpEF: A Novel Vascular Insight

By MedXY 08/13/2025

Empagliflozin alters peripheral microvascular responses in HFpEF patients, enhancing insulin-mediated vasodilation but reducing acetylcholine responsiveness, suggesting a targeted vascular mechanism distinct from general endothelial or smooth muscle effects.

Diabetes & Endocrinology Nephrology news Specialties

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

By MedXY 08/13/2025

The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.

Clinical Updates Diabetes & Endocrinology Nephrology news Specialties

Dual Renal Protection: Finerenone Plus Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

By MedXY 08/09/2025

Combining finerenone with empagliflozin provides superior reduction in albuminuria for patients with chronic kidney disease and type 2 diabetes, without increased adverse events.